Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Rituximab vs Radiation Therapy in Primary Ocular Adnexal MALT Lymphoma
NCT06190301Recruiting
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Dec 2023
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of rituximab (2 arms), sponsored by Zhongshan Ophthalmic Center. Primary endpoint: Cumulative occurrence rate of complications of grade >=2 at 5 years. Started Dec 2023; status: recruiting.
02
Drugs
rituximab
Beyond the preview
Go deeper on NCT06190301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06190301.